Anterior Uveitis in TINU — What to Do When Systemic Corticosteroids Fall Short

Clinical scenario

Tubulointerstitial nephritis and uveitis syndrome (TINU) commonly presents with anterior uveitis. While many patients require systemic treatment from the outset, a substantial proportion do not achieve adequate or lasting control with the initial course — raising the question of what comes next.

Anterior uveitis in TINU

In the acute phase, around one third of patients with TINU who have anterior uveitis respond to topical corticosteroids. The remaining two thirds require systemic corticosteroids, with a median treatment duration of approximately 2.5 months.

When the first line falls short

Systemic corticosteroids are the established initial step in this setting. The expected goals of that course are prompt resolution of ocular inflammation and renal recovery. When those goals are not reached — or when inflammation recurs during or after tapering — escalation to a next-line approach is warranted.

Next-line approach

At this stage, a steroid-sparing strategy involving immunomodulation therapy (IMT) is considered. The clinical objective extends beyond acute control: the focus shifts to sustaining ocular quiescence over a prolonged period before any withdrawal is attempted. The full regimen — including the specific approach and sequence for this situation — is detailed in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/ICU.0b013e3283318f9a

In the acute phase, around 1/3 of patients with TINU who have anterior uveitis will respond to topical corticosteroids, whereas 2/3 will require systemic corticosteroids (median duration of treatment is 2.5 months).

We institute IMT as required for improved anti-inflammatory control, to reduce recurrences upon steroid tapering, or to reduce unwanted steroid-related adverse effects, and seek to maintain quiescence for at least 12–24 months before withdrawing treatment.

View source ↗